GlassScriptPhysician profile
Shwetha Menon
NPI 1154013654
$1,877.78
in general payments reported to CMS, 2019-2025
20 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $260 · 2024: $455 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $363.02 | 2024-2025 | |
| Ucb, INC. | $326.10 | 2023-2025 | Rystiggo |
| Novartis Pharmaceuticals Corporation | $229.53 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $157.10 | 2024-2025 | Ingrezza |
| Genzyme Corporation | $103.92 | 2023 | |
| Neurelis, INC. | $94.37 | 2025 | Valtoco |
| Abbvie INC. | $89.26 | 2023-2025 | |
| Biogen, INC. | $69.89 | 2025 | Skyclarys, Spinraza |
| Teva Pharmaceuticals USA, INC. | $60.78 | 2024-2025 | Austedo Xr, Austedo Xr |
| Pfizer INC. | $51.64 | 2025 | |
| Eisai INC. | $46.40 | 2025 | |
| Csl Behring | $40.16 | 2024 | Hizentra |
| Grifols USA, LLC | $39.96 | 2025 | Gamunex-C |
| Janssen Biotech, INC. | $35.76 | 2025 | |
| Acadia Pharmaceuticals INC | $35.05 | 2024 | Nuplazid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $31.70 | 2025 | |
| Argenx US, INC. | $28.77 | 2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $26.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.95 | 2023 | |
| Genentech USA, INC. | $23.89 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shwetha Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.